Last reviewed · How we verify
TNFi
At a glance
| Generic name | TNFi |
|---|---|
| Also known as | Etanercept, Adalimumab, Golimumab, Certolizumab |
| Sponsor | Marie Hudson, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis (PHASE2)
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM) (PHASE4)
- Stand UP to Rheumatoid Arthritis (SUPRA) (NA)
- CD40L Antagonism in Rheumatoid Arthritis (RA) (PHASE2)
- Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNFi CI brief — competitive landscape report
- TNFi updates RSS · CI watch RSS
- Marie Hudson, MD portfolio CI